• Home
  • Practice Focus
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
    • How I Do It
    • TRIO Best Practices
  • Business of Medicine
    • Health Policy
    • Legal Matters
    • Practice Management
    • Tech Talk
    • AI
  • Literature Reviews
    • Facial Plastic/Reconstructive
    • Head and Neck
    • Laryngology
    • Otology/Neurotology
    • Pediatric
    • Rhinology
    • Sleep Medicine
  • Career
    • Medical Education
    • Professional Development
    • Resident Focus
  • ENT Perspectives
    • ENT Expressions
    • Everyday Ethics
    • From TRIO
    • The Great Debate
    • Letter From the Editor
    • Rx: Wellness
    • The Voice
    • Viewpoint
  • TRIO Resources
    • Triological Society
    • The Laryngoscope
    • Laryngoscope Investigative Otolaryngology
    • TRIO Combined Sections Meetings
    • COSM
    • Related Otolaryngology Events
  • Search

Is Betahistine Effective in the Treatment of Ménière’s Disease?

by Sean Holmes, MD, Anil K. Lalwani, MD, and Gauri Mankekar, MD, PhD • December 13, 2021

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
Print-Friendly Version

TRIO Best PracticeTRIO Best Practice articles are brief, structured reviews designed to provide the busy clinician with a handy outline and reference for day-to-day clinical decision making. The ENTtoday summaries below include the Background and Best Practice sections of the original article. To view the complete Laryngoscope articles free of charge, visit Laryngoscope.

You Might Also Like

  • Is Betahistine Effective in the Treatment of Ménière’s Disease?
  • Are Diuretics Useful in the Treatment of Meniére’s Disease?
  • Is Endolymphatic Sac Surgery Beneficial for Ménière’s Disease?
  • Is Hyperbaric Oxygen Effective in the Treatment of Sudden Sensorineural Hearing Loss?
Explore This Issue
December 2021

Background

Ménière’s disease (MD), or endolymphatic hydrops, is an idiopathic disorder commonly affecting adults between 40 and 60 years of age. Medical therapy is focused on treatment of acute episodes, prophylaxis, and mitigation of disease progression during the interval between attacks. Patients who receive no improvement after lifestyle changes are frequently treated with diuretic or betahistine or antihistamine therapies.

Betahistine, a partial H1 receptor agonist and potent H3 receptor antagonist, is widely used in Europe and the rest of the world in the treatment of MD; however, lacking FDA approval, it is unavailable in the United States. Betahistine is known to increase cochlear blood flow and is well tolerated at doses of 16 to 48 mg daily with no reported significant adverse events. It is contraindicated in patients with asthma, renal or cardiac disease, and allergies or hypersensitivities to the medication. In this Triological Society Best Practice, we review the current literature to determine whether betahistine is effective in the treatment of MD.

Best Practice

Though some studies show benefit, high-quality data demonstrating the efficacy of betahistine in the treatment of MD is absent. Despite mixed results, it remains popular due to a very low risk profile. Definitive large-scale randomized controlled trials with standardized diagnostic criteria, dosing regimens, and long-term follow-ups are required to assess the efficacy of betahistine in the treatement of MD. 

Filed Under: Otology/Neurotology, Otology/Neurotology, TRIO Best Practices Tagged With: Meniere's disease, treatmentIssue: December 2021

You Might Also Like:

  • Is Betahistine Effective in the Treatment of Ménière’s Disease?
  • Are Diuretics Useful in the Treatment of Meniére’s Disease?
  • Is Endolymphatic Sac Surgery Beneficial for Ménière’s Disease?
  • Is Hyperbaric Oxygen Effective in the Treatment of Sudden Sensorineural Hearing Loss?

The Triological SocietyENTtoday is a publication of The Triological Society.

Polls

Have you invented or patented something that betters the field of otolaryngology?

View Results

Loading ... Loading ...
  • Polls Archive

Top Articles for Residents

  • Applications Open for Resident Members of ENTtoday Edit Board
  • How To Provide Helpful Feedback To Residents
  • Call for Resident Bowl Questions
  • New Standardized Otolaryngology Curriculum Launching July 1 Should Be Valuable Resource For Physicians Around The World
  • Do Training Programs Give Otolaryngology Residents the Necessary Tools to Do Productive Research?
  • Popular this Week
  • Most Popular
  • Most Recent
    • Otolaryngologists as Entrepreneurs: Transforming Patient Care And Practice

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Continued Discussion And Engagement Are Essential To How Otolaryngologists Are Championing DEI Initiatives In Medicine

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • The Dramatic Rise in Tongue Tie and Lip Tie Treatment

    • Rating Laryngopharyngeal Reflux Severity: How Do Two Common Instruments Compare?

    • Is Middle Ear Pressure Affected by Continuous Positive Airway Pressure Use?

    • Otolaryngologists Are Still Debating the Effectiveness of Tongue Tie Treatment

    • Complications for When Physicians Change a Maiden Name

    • Physician Handwriting: A Potentially Powerful Healing Tool
    • Leaky Pipes—Time to Focus on Our Foundations
    • You Are Among Friends: The Value Of Being In A Group
    • How To: Full Endoscopic Procedures of Total Parotidectomy
    • How To: Does Intralesional Steroid Injection Effectively Mitigate Vocal Fold Scarring in a Rabbit Model?

Follow Us

  • Contact Us
  • About Us
  • Advertise
  • The Triological Society
  • The Laryngoscope
  • Laryngoscope Investigative Otolaryngology
  • Privacy Policy
  • Terms of Use
  • Cookies

Wiley

Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1559-4939